Catalog No.
DHD10814
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG
Clonality
Monoclonal
Target
CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P15391
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
UCART19
Clone ID
UCART19
Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer., PMID:40317083
Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies., PMID:38231412
An "off-the-shelf" CD2 universal CAR-T therapy for T-cell malignancies., PMID:37798328
Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia., PMID:36970059
Mechanistic Modeling of the Interplay Between Host Immune System, IL-7 and UCART19 Allogeneic CAR-T Cells in Adult B-cell Acute Lymphoblastic Leukemia., PMID:36970053
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial., PMID:36228643
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies., PMID:33308471
CAR T cell therapy: A new era for cancer treatment (Review)., PMID:31578576
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells., PMID:28123068